As the end of the 119th Congress comes into view, key House and Senate committees are making plans for what might turn out to be a busy work period either immediately before or after the midterm elections. Among the priority bills the health committees are readying are those addressing healthcare price transparency requirements. Passage of the strongest possible, and therefore also consumer-facing, version of this emerging effort would be a good step forward for American healthcare. Based on the bills now advancing, there is room for further improvement.
The outline of what Congress is currently considering, with broad support in both parties, has been visible for some time and is reflected in the similar but not identical approaches taken to date in the two chambers. In the House, the Energy and Commerce Committee voted unanimously to advance H.R. 9393, the Lower Costs, More Transparency Act of 2026. In the Senate, the Health, Education, Labor, and Pensions (HELP) Committee approved S. 2355, the Patients Deserve Price Tags Act, by a vote of 21 to 1.
Table 1, which is based on useful summaries posted online by a private firm in the case of the House bill and by the HELP committee for the Senate version, provides a high-level comparison of the main provisions of the competing measures alongside what is required by current federal regulations.
The approach taken on both sides of the Capitol is to use the existing regulatory requirements as the starting point for what would be codified in federal law and then to make changes to correct identified deficiencies and fill in gaps in disclosed pricing.
A major focus in both bills is on stronger enforcement tools. Some service providers see the transparency push as a costly political gesture that needs to be managed rather than embraced. This lack of enthusiasm has translated directly into cumbersome datasets filled with millions of lines of useless information. The emerging bills would take care of this problem by writing into federal law more precise disclosure terms and also meaningful penalties for persistent stonewalling.
To close gaps in the prices available in the market, both bills also would extend the disclosure framework to ambulatory surgical centers (ASCs), imaging centers, diagnostic labs, and the prescription drugs covered by insurance plans. These are service and product categories with significant room for patient discretion, and thus should be good candidates for more vigorous price competition. The House bill also imposes new reporting and transparency requirements on pharmaceutical benefit managers (PBMs).
The toughest challenge continues to be translating disclosed prices into information consumers, as opposed to employers, are incentivized to use to secure lower-priced services. It is often argued by insurers that the only prices that matter to patients are the cost-sharing amounts owed when getting care. It follows, they continue, that transparency should focus on helping patients see what they would pay after insurance has covered some of the costs. The provision in the Senate bill which forces providers to stick with the prices given to patients in Advanced Explanation of Benefits (AEOBs), with some exceptions, is an attempt to build off of the concern patients have around cost-sharing.
While patients certainly do worry about their out-of-pocket costs after insurance coverage, total prices are also important because they affect premiums, and high premiums for employer coverage translate directly into lower wages for workers.
Two additions to a final House-Senate compromise plan would sharpen the focus on helping consumers secure lower-priced care and not just lower cost-sharing.
First, Congress should authorize the executive branch to require pricing from all relevant providers, including physicians, for standardized definitions of high-volume clinical bundles. It is one thing to have access to prices for small dollar lab tests, office visits, or imaging services. It is another altogether if patients had ready access to prices for full apples-to-apples episode bundles, such as for hip replacement surgery, with nothing left out and no need for legwork on their part.
Second, Congress should allow patients to break free from their insurers and select lower-priced options whenever possible (some states are exploring similar “Right to Save” ideas). For instance, if an insurer’s in-network rate for an MRI is $2,000 while a local imaging center charges $500, patients should be allowed to benefit financially when choosing the imaging center over the hospital even if their insurers would fully pay for the hospital-based service (patients are often price insensitive after satisfying their deductibles). Taking this step would incentivize independent suppliers to lower their prices by enlarging their pools of potential customers.
Currently, forced price transparency has bipartisan support, but there is no guarantee it will be a priority in the future. If the door opens to passing a new bill later this year, it will be important to make full use of the opportunity.
Table 1. Comparison of Existing and Proposed Healthcare Price Transparency Requirements
| Provision | Current Rules | E&C Bill | Senate HELP Bill |
| Hospitals | – Must post machine-readable files for cash and negotiated rates – 300 shoppable services | – Codifies existing requirements – Median price option for posted cash prices | – Codifies existing requirements and requires plain language descriptions – HHS required to report on compliance |
| Hospital Enforcement | – Caps of $5500 per day for large hospital non-compliance | – Executive Attestation – Higher penalties | – Executive Attestation – Higher penalties |
| Ambulatory Surgical Centers | – No requirement beyond participation in insurance-focused good faith estimates | – ASCs must post machine-readable prices and plain language descriptions for 300 shoppable services but not rates negotiated with insurers – $300 per day fine for non-compliance | – Must post machine-readable prices and plain language descriptions of all negotiated rates and cash prices – $300 per day fine for non-compliance |
| Labs and Imaging | – No requirement beyond participation in insurance-focused good faith estimates | – Must post machine-readable prices and plain language descriptions of all negotiated rates and cash prices – $300 per day fine for non-compliance | – Must post machine-readable prices and plain language descriptions of all negotiated rates and cash prices – $300 per day fine for non-compliance |
| Insurers/PBMs | – Tools for estimating patient cost-sharing for services – Explanation of Benefits (EOB) Required – Advanced EOB also required but not yet enforced | – Prescription drug pricing required – PBM practices disclosed – More robust consumer-focused price comparison tools | – Required Explanation of Benefits (EOB) for services and Advanced EOB – Prohibits collections from patients if no itemized bill has been presented or for amounts in excess of an AEOB – Employer plans have access to all relevant pricing data – Executive attestation – $300 per member or $10 mil. penalty for non-compliance |
| Effective Date | – In effect except the AEOB requirement | – January 2028 | – Not stated |
Facts Only
* The House Energy and Commerce Committee voted unanimously to advance H.R. 9393.
* The Senate HELP Committee approved S. 2355 by a vote of 21 to 1.
* The legislative approach involves using existing regulatory requirements as a starting point for federal law codification and making corrections.
* Both bills focus on stronger enforcement tools, including precise disclosure terms and penalties for stonewalling.
* Proposed extensions cover ambulatory surgical centers (ASCs), imaging centers, diagnostic labs, and prescription drugs covered by insurance.
* The House bill imposes new reporting requirements on pharmaceutical benefit managers (PBMs).
* The Senate bill requires providers to adhere to prices given in Advanced Explanation of Benefits (AEOBs) with exceptions.
* Effective dates for the proposed measures vary, with one bill targeting January 2028.
* Hospital provisions include codification of existing requirements and median price options.
* Enforcement penalties are structured as $300 per day fines for non-compliance across various entities.
Executive Summary
Key House and Senate committees are preparing legislation concerning healthcare price transparency requirements, aiming to establish stronger measures for disclosing pricing. The approaches in both chambers reflect an effort to use existing regulations as a foundation, making adjustments to correct deficiencies in disclosed pricing. In the House, the Energy and Commerce Committee advanced the Lower Costs, More Transparency Act of 2026 (H.R. 9393), while the Senate HELP Committee approved the Patients Deserve Price Tags Act (S. 2355).
Both legislative efforts focus on strengthening enforcement tools to address provider reluctance toward transparency, seeking to move beyond cumbersome datasets by introducing precise disclosure terms and meaningful penalties for non-compliance. The proposals extend disclosure frameworks to categories including ambulatory surgical centers, imaging centers, diagnostic labs, and prescription drugs covered by insurance plans. A key tension exists regarding what should be disclosed: while patients focus on cost-sharing, the data also relates to total prices that affect premiums and wages.
The proposals include specific suggestions for further action, such as authorizing the executive branch to require pricing for standardized clinical bundles and allowing patients to seek lower-priced options across different providers to incentivize price competition.
Full Take
The movement toward mandatory price transparency reveals a tension between regulatory efficiency, provider resistance, and consumer empowerment. The current framework relies on post-hoc disclosure within existing structures; the proposed legislation seeks to shift this dynamic by imposing proactive, standardized pricing across all relevant services and products. The focus on enforcement—imposing penalties for non-compliance—suggests an understanding that mere data collection is insufficient; real change requires punitive mechanisms to overcome institutional inertia.
A significant pattern emerges around translating disclosed cost into actionable consumer choice. The debate shifts from what entities *must report* to how consumers should be *empowered* to use that information effectively, particularly concerning price discrimination embedded in insurance structures. The suggested additions—mandating pricing for episode bundles and enabling patient switching between providers based on total cost rather than just cost-sharing—point toward a paradigm where market forces are intentionally leveraged against established payment models.
The challenge lies in balancing the complexity of bundling high-volume services with ensuring that transparency directly results in tangible financial relief for patients, not simply more complex reporting for administrators. The long-term implication is whether this legislative push can successfully shift the locus of power regarding healthcare pricing from opaque institutional negotiations to transparent consumer negotiation.
Sentinel — Human
This text exhibits the structure, depth of context, and integration of complex data typical of high-level policy journalism, suggesting a human analytical hand rather than purely synthetic generation.